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Aims To investigate the prevalence of iron deficiency (ID) in heart failure (HF) patients with normal vs. abnormal red cell
indices (RCI), the associations between iron parameters and RCI, and prognostic consequences of ID independently
of RCI.
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Methods
and results
We analysed clinical data of 1821 patients with HF [mean age 66 ± 13 years; 71% men; New York Heart Association
class I/II/III/IV (11%/39%/44%/6%); left ventricular ejection fraction >45%: 19%]. Iron deficiency (ferritin <100 μg/L
or ferritin 100–299 μg/L with transferrin saturation <20%) was common irrespective of the presence of anaemia
(haemoglobin <12 g/dL in women and <13 g/dL in men) or low RCI, from 75% in anaemic subjects with low
mean corpuscular volume (MCV), mean corpuscular haemoglobin (MCH), and MCH concentration (MCHC), to
36% in non-anaemic subjects with MCV, MCH, and MCHC above the lower limit of normal. After adjustment for
clinical variables, iron parameters remained independently associated with haemoglobin, MCV, MCH, MCHC, mean
reticulocyte haemoglobin content (CHR), and red cell distribution width (RDW). In multivariable Cox proportional
hazard regression models there was a trend towards higher mortality in patients with vs. without ID when adjusted
for relevant HF prognosticators and MCH or MCHC (but not haemoglobin, CHR or RDW).
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Conclusions Patients with HF should be routinely screened for ID irrespective of the presence of anaemia or abnormal RCI. The
detrimental impact of ID on long-term survival in HF is partially independent of RCI.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Introduction
In recent years much attention has been paid to disordered iron
status and its adverse consequences for the symptomatology and
prognosis in heart failure (HF).1–4 The prevalence of iron defi-
ciency (ID) in chronic HF patients ranges from 50% in Europe5 to
61% in a multi-ethnic Asian population.6 Iron deficiency predicts
decreased exercise capacity,7 worse prognosis,4,5,8 and, impor-
tantly, appears to be a promising therapeutic target.9–13 Given the













. importance of sufficient availability of iron for unrestricted ery-
thropoiesis within the bone marrow,14,15 ID has been traditionally
perceived as an aetiological factor of anaemia.16 Indeed, in daily
clinical practice haemoglobin concentration and automatically mea-
sured red cell indices (RCI) are considered sensitive indicators of
systemic iron status,14,17 and HF patients without anaemia and with
normal RCI are rarely screened for ID. We compared the preva-
lence of ID in HF patients with normal and abnormal RCI, and
assessed the associations between different iron parameters and
© 2017 The Authors
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particular RCI. Furthermore, we evaluated the prognostic conse-
quences of ID independently of abnormal RCI or anaemia.
Methods
Patients
The study population comprised 1821 patients with chronic HF, from
five cohorts from: (i) Poland (two cohorts, n = 735),7,8 (ii) Spain
(one cohort, n = 789),18 and (iii) the Netherlands (two cohorts,
n = 297),19,20 as previously described by Klip et al.5 Detailed informa-
tion on inclusion and exclusion criteria for each cohort are available
online in the appendix to aforementioned paper.5 No patient received
blood transfusions, erythropoietin therapy, or intravenous iron therapy
at the time of inclusion. All study protocols have been approved by the
local ethics committees, and all patients gave written informed consent.
The study was conducted in accordance with the Helsinki declaration.
Haematological parameters, iron status,
and other laboratory measurements in
peripheral blood
Laboratory measurements were performed in the laboratories of par-
ticipating centres. Haematological measurements were made in fresh
venous blood with ethylenediaminetetraacetic acid (EDTA). After cen-
trifuging, the material was collected and frozen at –70∘C until further
laboratory analyses. The definition of anaemia, particular RCI evalu-
ated in this study, and cut-offs applied for the diagnosis of abnormal
RCI are presented in Table 1. Mean corpuscular volume (MCV), mean
corpuscular haemoglobin (MCH), and MCH concentration (MCHC)
were not measured in the Dutch cohorts, and red cell distribution
width (RDW) and reticulocyte haemoglobin content (CHR) were not
measured in the Dutch cohorts and in one Polish cohort (Tables 1 and
2). Both CHR and RDWwere measured in a limited number of subjects
(Table 2). The following blood biomarkers reflecting systemic iron sta-
tus were measured directly: ferritin (μg/L), serum iron (μg/dL), total
iron binding capacity (TIBC, μg/dL), and transferrin (mg/dL). Serum
ferritin was measured using an immunoassay based on electrochemi-
luminescence method. Serum iron and TIBC were assessed using a
substrate method. Transferrin measurements were available for most
patients and transferrin saturation (TSAT) was reported as a ratio of
0.7217 × serum iron and transferrin, multiplied by 100.21 When trans-
ferrin was not available, TSAT was calculated as a ratio of serum iron
and TIBC, multiplied by 100. Iron deficiency was defined as a ferritin
level <100 μg/L or serum ferritin 100–299 μg/L in combination with
a TSAT <20%, absolute ID as ferritin <100 μg/L, and functional ID
as ferritin 100–299 μg/L with transferrin saturation<20%.9,10 Plasma
level of N-terminal pro-B-type natriuretic peptide (NT-proBNP, pg/mL)
was measured using an immunoassay based on electrochemilumines-
cence with the Elecsys System (Roche Diagnostics GmbH, Mannheim,
Germany). Renal function was assessed estimating creatinine clearance
(CrCl, mL/min) using the Cockcroft–Gault equation.22
Clinical follow-up
Information regarding survival was obtained directly from patients
or their relatives, from the HF clinic databases or from the hospital
systems, and was available for 1519 patients (83%). The all-cause death



















































































.. survival analyses the length of follow-up of survivors and patients who
died later than 6 years after the enrolment was censored at 2190 days.
Statistical analyses
Most continuous variables had a normal distribution, and were
expressed as a mean ± standard deviation (SD) of the mean. The
inter-group differences were tested using the analysis of variance
(ANOVA) with post hoc Scheffé’s tests. NT-proBNP, ferritin, and TSAT
had a skewed distribution, and were log-transformed (a natural log-
arithm, ln) before inclusion in further analyses. These variables were
expressed as a median with an interquartile range, and the inter-group
differences were evaluated after the ln transformation. Categorized
variables were expressed as a number and a proportion (%), and the
inter-group differences were tested using the chi-square test.
To establish the associations between haemoglobin concentration,
RCI (MCV, MCH, MCHC, CHR, and RDW) and iron status (the pres-
ence of ID, serum iron, serum ferritin, and TSAT) we constructed a set
of multivariable linear regression models (haematological parameter as
dependent variable in the model) in which the power of these associ-
ations was adjusted for the following clinical variables: (i) age, gender,
body mass index (BMI); (ii) the severity [New York Heart Associa-
tion (NYHA) functional class, left ventricular ejection fraction (LVEF),
NT-proBNP] and aetiology of HF (ischaemic vs. non-ischaemic); (iii)
renal function (as assessed using CrCl); and (iv) major comorbidities
(arterial hypertension and diabetes).
The impact of ID (also absolute and functional ID separately), serum
ferritin, and TSAT on long-term mortality was tested: (i) unadjusted
(univariable models), and (ii) after the adjustment for key clinical
HF prognosticators (predefined: NT-proBNP, NYHA class and CrCl)
and either haemoglobin or one of RCI (MCV, MCH, MCHC, CHR,
and RDW) (five-variable models). The associations between variables
analysed and long-term mortality were evaluated using multivariable
Cox proportional hazard regression models.
A P-value of <0.05 was considered statistically significant. Statistical
analyses were performed using the STATISTICA 12 data analysis
software system (StatSoft Inc, Tulsa, OK, USA).
Results
Baseline characteristics of examined
patients with heart failure: prevalence of
iron deficiency in patients with anaemia
or abnormal red cell indices
Clinical characteristics, iron status, and haematological parame-
ters of 1821 examined patients with HF are presented in Table 2.
Absolute and functional subtypes of ID were detected in 33% and
19% of patients, respectively. Iron deficiency (either absolute or
functional) without anaemia, anaemia without ID, and the combi-
nation of both [iron deficiency anaemia (IDA)] were diagnosed in
32%, 12%, and 20% of subjects, respectively. In comparison with
non-anaemic patients without ID, subjects with IDAwere older, had
more severe HF symptoms, higher LVEF and plasma NT-proBNP,
and lower CrCl (Table 2). MCV, MCH, MCHC, and CHR below
the lower limit of normal were detected in 4%, 9%, 29%, and 10%
of patients, respectively, whereas RDW above the upper limit of
© 2017 The Authors
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Table 1 Definition of anaemia and abnormal red cell indices in patients with heart failure
Parameter Abbreviation Unit Abnormalities Reference number
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Haemoglobin Hb g/dL Anaemia: <12 g/dL for women
and <13 g/dL for men
33
Mean corpuscular volume MCV fL Low MCV: <81 fL for women
and <80 fL for men
35, 36
Mean corpuscular haemoglobin MCH pg Low MCH: <26 pg for women
and <27 pg for men
35, 36
Mean corpuscular haemoglobin concentration MCHC g/dL Low MCHC: <32 g/dL 35, 36
Mean reticulocyte haemoglobin content CHR pg Low CHR: <28 pg 34, 37, 38
Red cell distribution width RDW % High RDW: >14.5% 39
normal was present in 49% of subjects. Iron deficiency was com-
mon comorbidity in HF patients irrespective of either the presence
of anaemia or low RCI (Figures 1 and 2), from 75% in anaemic sub-
jects with low MCV, MCH, and MCHC, to 36% in patients without
anaemia and with these three RCI above the lower limit of normal
(Figure 2).
Associations between iron status and
haemoglobin concentration and red cell
indices
In univariable linear regression analyses the presence of ID and
lower iron parameters (serum iron, serum ferritin, and TSAT)
correlated with lower haemoglobin concentration, MCV, MCH,
MCHC, and CHR, and with higher RDW (all P < 0.001, Table 3).
After the adjustment for relevant clinical variables (age, gen-
der, BMI, severity and aetiology of HF, renal function, and
comorbidities), in multivariable linear regression models ID and
lower iron parameters remained independently associated with
lower haemoglobin, MCV, MCH, MCHC, and CHR, and with
higher RDW (all P < 0.001, Table 3).
Iron status, haematological parameters,
and survival in patients with heart failure
Patients without available follow-up (compared with subjects with
available follow-up) were more often female (42 vs. 26%, respec-
tively, P < 0.001), had less severe HF symptoms (NYHA class I or
II: 66% vs. 46%, P < 0.001), were older (73 ± 11 years vs. 64 ± 13
years, P < 0.001), had higher BMI (28.4 ± 6.1 kg/m2 vs. 27.5 ± 4.8
kg/m2, P = 0.007), LVEF (46 ± 16% vs. 33 ± 13%, P < 0.001), and
CrCl (103 ± 77 vs. 91 ± 55, P < 0.001), and lower haemoglobin
(12.5 ± 1.8 vs. 13.6 ± 1.8 g/dL, P < 0.001), and were more often
iron-deficient (60% vs. 50%, P = 0.002). Importantly, these two
groups of patients had similar NT-proBNP (median 1837 vs. 1395
pg/mL, P = 0.09).
In 1519 patients studied the mean duration of follow-up (after
censoring) was 855 ± 571 days (median: 699 days) whereas the
mean time to death (after censoring, n = 422) was 604 ± 501 days
(median: 480 days). Higher NYHA class and NT-proBNP, and lower






























































.. all-cause mortality in patients studied [for the three-variable Cox
proportional hazard regression model (𝜒2 = 213.4, P < 0.001):
NYHA class hazard ratio (HR) per 1 class increase 1.51, 95%
confidence interval (CI) 1.29–1.77, P < 0.001; NT-proBNP HR
= 1.48 per 1 ln pg/mL increase, 95% CI 1.36–1.62, P < 0.001;
CrCl HR = 0.95 per 10 mL/min increase, 95% CI 0.93–0.98,
P = 0.002). The MCV, MCH, MCHC, CHR, and RDW were
measured in 1136, 1114, 1114, 276, and 605 patients with available
follow-up, respectively. In univariable Cox proportional hazard
regression analyses the following haematological parameters were
associated with increased all-cause mortality: lower haemoglobin
concentration (HR = 0.86 per 1 g/dL increase, 95% CI 0.81–0.91,
P < 0.001), MCH (HR = 0.94 per 1 pg increase, 95% CI 0.90–0.98,
P = 0.008), MCHC (HR = 0.89 per 1 g/dL increase, 95% CI
0.83–0.95, P < 0.001), CHR (HR = 0.91 per 1 pg increase, 95%
CI 0.86–0.97, P = 0.002), and higher RDW (HR = 1.16 per 1%
increase, 95% CI 1.10–1.24, P < 0.001).
In univariable Cox proportional hazard regression analyses the
presence of ID (also absolute and functional ID separately) and
lower TSAT (but not serum ferritin) predicted higher long-term
all-cause mortality in patients with HF (Table 4, all P < 0.05). Impor-
tantly, when adjusted for aforementioned relevant HF prognostica-
tors (NT-proBNP, NYHA class, CrCl) and either MCH or MCHC
(but not haemoglobin concentration, CHR, or RDW) there was
still a trend towards higher mortality in patients with either ID or
lower TSAT (all P < 0.1) (Table 4).
Discussion
The major findings of this study are: (i) despite evident associations
between iron status and RCI, ID is a common comorbid condition
in HF patients irrespective of the presence of anaemia and/or
abnormal RCI; (ii) ID predicts increased long-term mortality in
these patients, which is partially independent of low RCI.
Owing to the traditional view of ID as a nutritional deficiency
leading to IDA, low RCI have been considered sensitive indicators
of decreased iron availability for haematopoietic tissues for more
than 50 years.23 Indeed, low MCV, MCH, and MCHC reflect the
advanced stage of iron-restricted erythropoiesis within the bone
marrow, and the picture of microcytic and hypochromic anaemia
constitutes the typical laboratory presentation of IDA.14,15,17
© 2017 The Authors
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Table 2 Baseline characteristics of patients with heart failure according to the presence of anaemia and/or iron
deficiency








. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age, years 1821 66 ± 13 61 ± 13 66 ± 13*** 69 ± 12*** 72 ± 11***
Sex, male 1821 1298 (71) 533 (81) 381 (66)*** 155 (72)** 229 (62)***
BMI, kg/m2 1772 27.6 ± 5.1 28.0 ± 5.0 27.5 ± 4.9 26.8 ± 4.7 27.8 ± 5.6
SBP, mmHg 1736 121 ± 21 119 ± 20 121 ± 22 120 ± 24 123 ± 21*
Heart rate, b.p.m. 1740 76 ± 15 77 ± 15 76 ± 15 76 ± 14 75 ± 14










HF aetiology, CAD 1821 1042 (57) 376 (57) 332 (58) 124 (57) 210 (57)
LVEF, % 1821 35 ± 15 32 ± 13 34 ± 14 38 ± 17*** 41 ± 17***
NT-proBNP, pg/mL 1804 1440 (575–3553) 1098 (461–2360) 1409 (506–3481)* 1898 (794–5746)*** 2185
(977–4966)***
CrCl, mL/min 1800 93 ± 59 102 ± 62 91 ± 46** 83 ± 52*** 84 ± 72***
Arterial hypertension, yes 1813 1065 (59) 349 (53) 310 (54) 149 (69)*** 257 (70)***
Diabetes, yes 1805 664 (37) 197 (30) 184 (32) 92 (43)*** 191 (52)***
Treatment
ACEI or/and ARB, yes 1802 1599 (89) 618 (94) 518 (91)* 177 (84)*** 286 (78)***
𝛽-blocker, yes 1816 1642 (90) 608 (92) 516 (90) 197 (91) 321 (87)**
Aldosterone antagonist, yes 1612 821 (51) 330 (55) 238 (50) 102 (51) 151 (46)**
Digoxin, yes 1718 420 (24) 194 (31) 124 (24)* 46 (22)* 56 (15)***
Statin, yes 1809 1164 (64) 433 (66) 364 (63) 139 (65) 228 (62)
Loop diuretic, yes 1820 1455 (80) 486 (74) 460 (80)** 181 (84)** 328 (88)***
Antiplatelets, yes 1817 927 (51) 340 (52) 287 (50) 115 (53) 185 (50)
Anticoagulants, yes 1719 733 (43) 253 (40) 225 (44) 91 (43) 164 (45)
Indices of iron status
Iron, μg/dL 1821 79 ± 44 107 ± 43 66 ± 36*** 78 ± 45*** 47 ± 23***
Ferritin, μg/L 1821 150 (79–274) 256 (164–397) 83 (54–128)*** 319 (198–472)* 78 (46–142)***
TSAT, % 1821 21 (14–31) 30 (24–40) 17 (13–23)*** 24 (20–30)*** 13 (9–17)***
Haemoglobin and RCI
Haemoglobin, g/dL 1821 13.4 ± 1.9 14.6 ± 1.3 14.1 ± 1.1*** 11.4 ± 1.3*** 11.3 ± 1.1***
MCV, fL 1437 91.0 ± 6.0 92.0 ± 5.1 91.0 ± 5.6 91.9 ± 7.2 88.7 ± 6.2***
MCH, pg 1407 29.9 ± 2.6 31.0 ± 2.1 29.9 ± 2.2*** 29.9 ± 3.1*** 28.2 ± 2.5***
MCHC, g/dL 1407 32.9 ± 1.9 33.8 ± 1.8 32.9 ± 1.5*** 32.5 ± 1.9*** 31.8 ± 1.6***
CHR, pg 563 32.3 ± 3.6 33.5 ± 2.7 32.7 ± 2.5 32.7 ± 4.3 30.5 ± 4.2***
RDW, % 897 15 ± 2 14 ± 2 15 ± 2** 15 ± 2*** 16 ± 2***
Data are presented as a mean ± standard deviation of the mean, a median (with lower and upper quartiles) or n (with %), where appropriate. n, number of patients for whom
data were available. Anaemia was defined as haemoglobin <12 g/dL in women and <13 g/dL in men. ID was defined as ferritin <100 mg/L, or 100–299 mg/L with transferrin
saturation <20%.
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CAD, coronary artery disease; CHR, mean reticulocyte haemoglobin
content; CrCl, creatinine clearance; HF, heart failure; ID, iron deficiency; LVEF, left ventricular ejection fraction; MCH, mean corpuscular haemoglobin; MCHC, mean corpuscular
haemoglobin concentration; MCV, mean corpuscular volume; NT-proBNP,N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; RCI, red cell indices;
RDW, red cell distribution width; SBP, systolic blood pressure; TSAT, transferrin saturation.
P-values for the comparison with the group ‘No ID and no anaemia’: *P < 0.05, **P < 0.01, ***P < 0.001 (post hoc).
For details, see the Methods section.
Increased RDW is another indicator of IDA, but this parameter
is also elevated in megaloblastic anaemia.3,24 In comparison with
aforementioned parameters, decreased haemoglobin in reticulo-
cytes, as reflected by low CHR, characterizes the very early stages
of defective erythropoiesis due to ID, and is of particular clinical
importance as it allows one to monitor the response to parenteral










.. large international cohort of HF patients with both reduced
and preserved LVEF, we have shown that although haemoglobin
concentration and particular RCI (MCV, MCH, MCHC, CHR,
and RDW) closely correlate with different iron parameters (the
presence of ID, serum iron, serum ferritin, and TSAT) inde-
pendently of other clinical and laboratory variables (including
aetiology and severity of HF and important comorbidities), ID
© 2017 The Authors
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Figure 1 The prevalence of iron deficiency in patients with heart failure according to the presence of anaemia or abnormal red cell indices.
LLON, lower limit of normal; ULON, upper limit of normal; MCH, mean corpuscular volume; MCH, mean corpuscular haemoglobin; MCHC,
mean corpuscular haemoglobin concentration; CHR, mean reticulocyte haemoglobin content; RDW, red cell distribution width. (For the
definition of iron deficiency, anaemia, and abnormal red cell indices, see the Methods section and Table 1).
also constitutes a frequent comorbidity in patients without any
haematological abnormalities. It needs to be emphasized that even
in non-anaemic [according to the World Health Organization
(WHO) definition] patients with MCV, MCH, and MCHC above
the lower limit of normal, the prevalence of ID reached 36%.
An observed considerable prevalence of ID irrespective of the
presence of anaemia or abnormal RCI suggests that although dis-
ordered iron homeostasis represents one of the causes of anaemia
in HF,2,25 many patients with cardiac failure and concomitant ID
will not develop haematological abnormalities. Indeed, in recent
years complex derangements regarding iron status in HF have
been elucidated,1,3 and the traditional view of ID as a leading cause
of anaemia25 in these patients has been revised.2 With regard to
pathophysiology, ID contributes to the cardiorenal–anaemia axis
in patients with HF,26 and the complex interplay between cardiac
failure, renal dysfunction, ID, and anaemia has been emphasized in
a paper by Macdougall et al.,27 in which the authors introduced the
term cardiorenal–anaemia–iron deficiency syndrome (CRAIDS).
Nevertheless, the aetiology of anaemia in HF is multifactorial,2
with several contributing and overlapping pathomechanisms such
as renal impairment, systemic inflammation, ID, and haemodilution,
to name but a few.2,28,29 Importantly, the present study confirms
that in patients with HF ID should not only be perceived as a cause
of anaemia, but an equivalent comorbidity that can occur without









































.. In the present study we have also demonstrated that in patients
with HF with either reduced or preserved LVEF, concomitant ID
predicts increased long-term all-cause mortality, which is partially
independent of RCI. In univariable Cox proportional hazard regres-
sion analyses both iron status (ID and lower TSAT, but not serum
ferritin) and RCI (lower haemoglobin, MCH, MCHC, CHR, and
higher RDW, but not MCV) predicted increased long-term mor-
tality. Further, in multivariable analyses there was still a trend
towards higher mortality in patients with either ID (including func-
tional but not absolute subtype of this comorbidity separately)
or lower TSAT (all P < 0.1), when adjusted for relevant clin-
ical HF prognosticators (neurohormonal activation, severity of
HF symptoms and renal function) and MCH or MCHC (but not
haemoglobin, CHR or RDW). Our results are consistent with
previous findings demonstrating the detrimental prognostic con-
sequences of ID in patients with either stable or acute HF.3,6,8,31
Importantly, in the patients with HF studied the trend towards
higher mortality was associated more with functional than abso-
lute ID, and serum ferritin, reflecting body iron stores, was not
related to survival in this population. From the pathophysiologi-
cal point of view, functional ID results from reduced availability of
iron for iron-utilizing cells (e.g. erythropoietic), and is promoted by
increased systemic inflammation.2 Importantly, although patients
with more severe HF symptoms are characterized by lower fer-
ritin, TSAT, hepcidin (key regulator of iron metabolism), and
haemoglobin, and by increased circulating inflammatory biomark-
ers, the associations between iron and inflammatory parameters
© 2017 The Authors
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Figure 2 The prevalence of iron deficiency in patients with heart failure according to the presence of anaemia and the number of decreased
red cell indices (RCI) (of the following three: mean corpuscular volume, mean corpuscular haemoglobin, and mean corpuscular haemoglobin
concentration). LLON, lower limit of normal. For the definition of iron deficiency, anaemia, and decreased RCI, see the Methods section and
Table 1.
Table 3 Associations between iron status and haemoglobin concentration and red cell indices in patients with heart
failure
Haemoglobin and red cell indices (dependent variable)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ID and iron parameters Applied adjustment† Haemoglobin (g/dL) MCV (fL) MCH (pg) MCHC (g/dL) CHR (pg) RDW (%)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ID (yes vs. no) None –0.21*** –0.17*** –0.31*** –0.28*** –0.24*** 0.21***
ID (yes vs. no) 10 clinical variables –0.10*** –0.17*** –0.25*** –0.19*** –0.23*** 0.14***
Iron (μg/dL) None 0.39*** 0.19*** 0.38*** 0.36*** 0.34*** –0.28***
Iron (μg/dL) 10 clinical variables 0.26*** 0.21*** 0.30*** 0.23*** 0.36*** –0.20***
Ferritin (ln μg/L) None 0.16*** 0.15*** 0.25*** 0.21*** 0.21*** –0.14***
Ferritin (ln μg/L) 10 clinical variables 0.08*** 0.16*** 0.22*** 0.16*** 0.22*** –0.12***
TSAT (ln %) None 0.35*** 0.29*** 0.46*** 0.38*** 0.48*** –0.33***
TSAT (ln %) 10 clinical variables 0.22*** 0.32*** 0.42*** 0.27*** 0.50*** –0.24***
Data are presented as standardized regression coefficients 𝛽 (both in univariable and multivariable models) between haematological parameters (dependent variable in the
multivariable model) and indices of iron status.
CHR, mean reticulocyte haemoglobin content; ID, iron deficiency; MCH, mean corpuscular haemoglobin; MCHC, mean corpuscular haemoglobin concentration; MCV, mean
corpuscular volume; RDW, red cell distribution width; TSAT, transferrin saturation.
†10 clinical variables: age, gender, body mass index, New York Heart Association functional class, aetiology of heart failure, left ventricular ejection fraction, N-terminal
pro-B-type natriuretic peptide [natural logarithm (ln)], estimated creatinine clearance, concomitant arterial hypertension, and diabetes. Anaemia was defined as haemoglobin
<12 g/dL in women and <13 g/dL in men. ID was defined as ferritin <100 μg/L, or 100–299 μg/L with TSAT <20%.
***P < 0.001. For details see the Methods section.
are more complex than would be expected: for example, serum
high-sensitivity C-reactive protein correlates neither with ferritin
nor with hepcidin in these patients.31 The present study confirms,
that comorbid ID is not simply the feature of advanced HF, and
detrimental impact of ID on long-term survival in these patients
is partially independent of either HF severity or decreased RCI.
Further studies regarding the impact of ID on the natural history











.. It should be acknowledged that although current 2016 European
Society of Cardiology guidelines for the diagnosis and treatment
of acute and chronic HF32 clearly recommend searching for
comorbidities such as ID in all patients with newly diagnosed HF
(class of recommendation I, level of evidence C), in daily clinical
practice, patients with normal RCI and without anaemia have
rarely assessed ferritin and TSAT. The results of the present study
confirm that all patients with HF should be routinely screened
© 2017 The Authors
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for ID, irrespective of the presence or absence of haematological
abnormalities, as these pathologies are not simply parallel. More-
over, we have shown that a detrimental impact of ID on long-term
prognosis in HF patients is partially independent of haematological
abnormalities (i.e. decreased RCI). This is another premise for
the routine assessment of iron parameters in HF patients to
improve the risk stratification process in subjects who are usually
not suspected of ID. An active screening for ID in patients with
symptomatic HF with reduced LVEF would allow clinicians to
identify more potential beneficiaries of intravenous iron therapy.32
Importantly, there is no direct evidence of whether intravenous
iron therapy improves outcomes in HF patients (also irrespective
of baseline haematological status).
Limitations
It should be emphasized that there is no universal lower limit
of normal blood haemoglobin concentration (i.e. the definition
of anaemia). In the present study the definition of anaemia
was based on the WHO report (haemoglobin concentration
<12 g/dL for women and <13 g/dL for men) from 1968,33
and the same definition is mentioned in the 2016 ESC guide-
lines for the diagnosis and treatment of acute and chronic HF.32
Although this definition of anaemia is widely accepted and com-
monly applied in epidemiological studies (including studies regard-
ing HF patients), the appropriateness of these cut-offs remains
very controversial and has been criticized.34 Analogously to
haemoglobin, in the present study, the lower limits of normal
MCV, MCH, and MCHC were defined according to the WHO
document based on US Second National Health and Nutri-
tion Examination Survey (NHANES II)34,36 (Table 1), and these
cut-offs also may not be optimal for the contemporary Europeans
with HF.
Furthermore, the follow-up was available for 1519 patients only
(83%), which is a potential source of bias. Compared with subjects
included in survival analyses, patients without available follow-up
had a different clinical profile: they were older and more often
female, had less severe HF symptoms, higher LVEF, better renal
function, lower haemoglobin, and, finally, they were more often
iron-deficient. Importantly, MCV, MCH, MCHC, CHR, and RDW
were not measured in all patients with available follow-up (see the
Results section).
Another limitation of the study is that although patients did
not receive blood transfusions, erythropoietin therapy, or intra-
venous iron therapy at the time of inclusion, we do not have data
regarding potential iron therapy (either intravenous or oral) or
therapy with erythropoiesis-stimulating agents during the follow-up
period.
Conclusions
The present study confirms that, in patients with HF, ID should not
only be perceived as a cause of anaemia, but an equivalent comorbid
condition that can occur without haematological abnormalities



















































































.. detrimental impact of ID on long-term survival in HF patients is
partially independent of decreased RCI. Patients with HF should be
routinely screened for ID irrespective of the presence of anaemia
or abnormal RCI.
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